June 2026 confirmed a defining trend in rare disease innovation: success is no longer measured by clinical breakthroughs alone. Increasingly, it depends on the ability to navigate an evolving regulatory landscape, secure strategic investment, and deliver therapies to the patients who need them.
On the regulatory front, the FDA kept signaling greater flexibility for transformative medicines — supporting accelerated approval pathways for gene therapies from uniQure and REGENXBIO, granting RMAT designation to Prime Medicine’s gene-editing programme for chronic granulomatous disease, and reinforcing biomarker-driven evidence as a viable path to approval. The EMA struck a different note: its recommendation to revoke Tavneos’ marketing authorisation was a reminder that regulatory innovation must stay grounded in rigorous clinical evidence.
The month also spotlighted the broader ecosystem needed to turn science into patient benefit. In the UK, LifeArc’s integration of the Rare Therapies Launch Pad reinforced a national commitment to accelerating access to individualised medicines. In the US, Medicaid changes under the OBBBA — now moving into implementation — raised fresh concerns about continuity of care for people living with rare diseases. And on the financing side, major investments in non-viral gene delivery, RNA editing, rare kidney disease, and neuromuscular disorders showed where the industry is placing its bets for the next wave of rare disease therapeutics.
1. Clinical & patient access news
This month brought a wave of regulatory wins for rare disease therapies, alongside a notable setback and growing access concerns. The FDA advanced several programmes through orphan and pediatric designations, an RMAT designation, and agreements to support accelerated approval pathways for gene therapies in Huntington’s disease and Hunter syndrome, while new initiatives such as the Rare Disease Endpoint Advancement pilot and a « Plausible Mechanism Framework » pointed toward greater regulatory flexibility. Counterbalancing this momentum, the EMA recommended revoking a vasculitis therapy’s authorisation over trial-conduct deficiencies.
Gen1E Life Sciences announced that the FDA granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to GEN-1123, its investigational gene therapy for Duchenne muscular dystrophy (DMD). GEN-1123 is an AAV-based micro-dystrophin gene therapy designed to deliver a functional version of the dystrophin gene to skeletal and cardiac muscle, with the aim of restoring dystrophin expression and slowing disease progression in patients with DMD. The dual FDA designations provide regulatory incentives, including development support, market exclusivity upon approval, and potential eligibility for a Priority Review Voucher, reinforcing the program’s advancement in the rare neuromuscular disease landscape.
Novartis reported positive Phase 1/2 data for del-zota (delpacibart zotadirsen), an investigational antibody oligonucleotide conjugate (AOC) therapy for limb-girdle muscular dystrophy type 2E (LGMD2E). The therapy significantly increased beta-sarcoglycan protein expression and showed improvements across multiple biomarkers of muscle health. The encouraging data support regulatory discussions and reinforce the potential of AOC technology to deliver RNA therapeutics directly to muscle tissue in rare neuromuscular diseases.
uniQure announced that the FDA agreed existing Phase I/II data for AMT-130, an AAV5 gene therapy for Huntington’s disease, could support an accelerated approval application. The one-time gene therapy lowers production of mutant huntingtin protein through microRNA-mediated gene silencing. The FDA’s decision represents a major regulatory win and could allow approval without a conventional Phase 3 trial.
REGENXBIO announced that the FDA reversed its earlier position and agreed that existing clinical and biomarker data could support accelerated approval of Navsunli (clemidsogene lanparvovec) for Hunter syndrome (MPS II). Navsunli is a one-time AAV gene therapy designed to restore iduronate-2-sulfatase (IDS) activity. The FDA no longer requires an additional placebo-controlled trial, representing an important regulatory success for ultra-rare disease gene therapies.
Prime Medicine announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, its investigational ex vivo prime editing therapy for chronic granulomatous disease (CGD), a rare inherited primary immunodeficiency most commonly caused by mutations in the CYBB gene, which encodes the gp91^phox^ subunit of the NADPH oxidase complex. These mutations impair the ability of phagocytes to generate reactive oxygen species required to kill invading bacteria and fungi, resulting in recurrent, severe infections and chronic inflammation.
PM359 uses Prime Medicine’s Prime Editing platform to precisely correct the disease-causing mutation in a patient’s own hematopoietic stem cells before reinfusion, with the goal of restoring normal immune cell function through a one-time treatment. The RMAT designation recognizes the therapy’s potential to address a serious unmet medical need and provides enhanced FDA interactions and an expedited development pathway.
The European Medicines Agency recommended revoking the marketing authorization for Tavneos (avacopan) after concluding that the pivotal clinical trial supporting approval contained significant Good Clinical Practice deficiencies and unreliable efficacy data. Although Tavneos had been approved for ANCA-associated vasculitis, the EMA determined that subsequent evidence did not sufficiently confirm its clinical benefit, making this one of the most significant rare disease regulatory setbacks of 2026.
Sanofi announced that Nexviazyme (avalglucosidase alfa) met all primary and secondary endpoints in the Phase 3 Baby-COMET study in treatment-naïve infants with infantile-onset Pompe disease (IOPD). The primary endpoint was the proportion of patients alive and free of invasive ventilation after 52 weeks of treatment, with the study also demonstrating positive outcomes across all secondary endpoints, including survival free from invasive ventilation at 12 and 18 months and improvements in disease progression measures.
Nexviazyme is an enzyme replacement therapy (ERT) that delivers a recombinant form of acid alpha-glucosidase (GAA) with enhanced uptake into muscle cells to reduce glycogen accumulation, the underlying cause of Pompe disease. The positive Phase 3 results support a planned U.S. regulatory submission for an expansion of the therapy’s indication to infants with IOPD, a severe lysosomal storage disorder that is rapidly fatal without treatment.
Patient access
EU
- UK — Rare Therapies Launch Pad Moves to LifeArc
On June 24, LifeArc announced it will integrate the Rare Therapies Launch Pad (RTLP) into its organisation to accelerate the development, delivery, and access of individualised medicines for people with rare diseases. The RTLP is a UK-led multi-stakeholder initiative involving Genomics England, University of Oxford, Great Ormond Street Hospital, Mila’s Miracle Foundation, and others.
Among its achievements, the RTLP helped develop a world-first regulatory master protocol for individualised medicines, approved by the MHRA — a model for how flexible regulation can enable safe and efficient clinical translation of personalised therapies.
US
- FDA — Regulatory Acceleration & New Endpoints Program
FDA’s CBER is accepting applications through June 30, 2026 for the Rare Disease Endpoint Advancement (RDEA) Pilot Program, supporting the development of novel efficacy endpoints for rare disease drug development.
At FDA Rare Disease Day 2026, Commissioner Martin Makary highlighted a new « Plausible Mechanism Framework » for ultra-rare and individualised therapies where traditional randomised trials may not be feasible, and noted a national priority voucher pilot program that can compress review timelines from 10–12 months down to 1–2 months.
- Coverage Concerns — Medicaid & the OBBBA
This remains the most pressing access threat for rare disease patients in the US in 2026:
The One Big Beautiful Bill Act (OBBBA), passed in mid-2025, made significant changes to Medicaid that will shift costs to states and impose new requirements, with an estimated 10 million people at risk of losing coverage. Key changes include work and community engagement requirements (80 hours/month starting January 2027) and mandatory eligibility verification every six months.
For rare disease patients with fluctuating conditions — such as myasthenia gravis or mitochondrial disorders — proving medical frailty during a period of remission to qualify for exemptions is particularly difficult, and the cycle of « churn » from frequent redeterminations risks disrupting access to critical therapies.
As of June 2026, CMS has issued only limited preliminary guidance on the medical frailty exemption, with many key unknowns remaining, including the level of discretion states will have in defining and implementing work requirements.
2. Financing & Partnerships
Dealmaking in rare diseases remained robust this month, with significant capital directed toward novel delivery platforms and high-value therapeutic-area expansions. Investors backed alternatives to conventional viral vectors, while several major pharmaceutical players committed substantial upfront and milestone payments to build out their pipelines—most notably in rare kidney disease, through RNA-editing and BTK-inhibitor collaborations, and in neuromuscular disease, via a multi-billion-dollar acquisition. Together, these transactions underscore continued confidence in rare disease innovation and the strategic premium placed on differentiated modalities.
Financing: SonoThera closed a $125 million Series B financing to advance its non-viral gene delivery platform for genetic diseases. The company combines ultrasound technology with engineered microbubbles to deliver genetic medicines directly to target tissues, offering a potential alternative to viral vectors such as AAV.
Type: Series B financing / Gene therapy platform
Deal: Ascidian Therapeutics and Eli Lilly and Company entered a research collaboration worth up to $1.9 billion to develop RNA exon-editing therapies for kidney diseases, including rare genetic renal disorders. Ascidian will receive an upfront payment and is eligible for development, regulatory, and commercial milestone payments.
Type: Research collaboration / RNA editing / Rare kidney disease
Deal: Travere Therapeutics licensed an investigational Bruton’s tyrosine kinase (BTK) inhibitor from Everest Medicines in a deal valued at up to $1.03 billion. The therapy is being developed for IgA nephropathy and other rare immune-mediated kidney diseases, strengthening Travere’s nephrology portfolio beyond FILSPARI.
Type: Licensing agreement / Rare kidney disease
Deal: Servier agreed to acquire the muscular dystrophy business of Edgewise Therapeutics in a transaction worth up to $2.65 billion, including upfront and milestone payments. The acquisition adds late-stage programs for Duchenne and Becker muscular dystrophy, reinforcing Servier’s rare neuromuscular disease pipeline.
Type: Acquisition / Rare neuromuscular disease portfolio expansion
3. Research breakthroughs
A Single Test to Rule Them All? Long-Read Sequencing Reshapes Rare Disease Diagnostics
For patients with rare genetic diseases, reaching a diagnosis often means navigating a long sequence of separate tests — each targeting a specific type of genetic variant, each adding time and uncertainty. A landmark study published in the New England Journal of Medicine on June 13, 2026 suggests this fragmented process may soon be a thing of the past.
Researchers from Radboud University Medical Center and Maastricht UMC+ demonstrated that long-read genome sequencing (lrGS) can replace up to 15 standard diagnostic tests with a single, comprehensive assay. In a head-to-head comparison involving 832 patients, lrGS yielded a conclusive diagnosis in 19.2% of cases, versus 16.5% with standard-of-care testing — a meaningful gain in a field where every undiagnosed patient carries an enormous personal and systemic cost.
The advantage lies in what the technology can see. Unlike conventional short-read sequencing, long-read methods capture structural variants, repeat expansions, and other complex genomic changes that routinely escape detection. The team also modeled adoption across their centers’ full annual caseload of over 15,000 patients, confirming a net diagnostic gain at scale.
The authors recommend lrGS as the primary first-tier test for rare genetic disorders. For clinicians, researchers, and developers in the rare disease space, this study marks a clear inflection point in genomic diagnostics.
Upcoming events
📅 September 9–10, 2026 — Clinical Trials in Rare Diseases Conference 2026 — Princeton Marriott at Forrestal, Princeton, NJ, USA Focused on innovative clinical trial design, patient recruitment, and regulatory strategies for rare disease therapeutics, connecting academia, biotech, and regulators.
📅 September 14–15, 2026 — 2nd European Congress on Rare Diseases and Orphan Drugs 2026 — London, United Kingdom International forum featuring researchers, clinicians, policymakers, and pharmaceutical experts discussing new advances in diagnosis, orphan drug development, and health policy.
📅 October 22–23, 2026 — 4th International Conference on Rare Diseases and Orphan Drugs 2026 — Barcelona, Spain Global scientific conference themed “From Discovery to Cure: Transforming Rare Disease Care,” highlighting cutting‑edge research, therapeutic innovation, and patient‑centered care models.
📅 October 25–27, 2026 — NORD Rare Diseases & Orphan Products Breakthrough Summit 2026 — Washington, DC, USA Hosted by the National Organization for Rare Disorders (NORD), this premier U.S. summit unites patients, researchers, regulators, and biotech innovators to accelerate progress in rare disease treatments and policy.
📅 October 26–28, 2026 — World Orphan Drug Congress Europe — Amsterdam, Netherlands Leading global forum dedicated to rare disease drug development, orphan drug regulation, and market access, featuring stakeholders from biotech, pharma, patient advocacy groups, and regulators discussing advanced therapies including gene therapy, CRISPR, and RNA-based treatments.
📅 November 10–12, 2026 — BIO-Europe 2026 — Cologne, Germanny One of the largest global biotech partnering conferences, bringing together biopharma companies, investors, and rare disease developers to accelerate licensing deals, cross-border partnerships, and orphan drug collaborations across gene therapy, RNA therapeutics, and ultra-rare indications.